CClinicalTrials.gg
Sign In
Status unknownNCT01088269Updated Sep 14, 2017

Blood Pressure Assessment in Atrial Fibrillation

An observational study in Atrial Fibrillation, sponsored by University of Athens. Status unknown at 1 site in Greece. Open to participants aged 25 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-09-14.

Sponsored by University of Athens · Observational

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
25 Years to 85 Years
Sex
All
01

Study summary

This is a cross-sectional study including patients with permanent atrial fibrillation. Assessment will include:

  • clinic blood pressure measurements (mercury sphygmomanometer and automated oscillometric device)
  • 24-hour ambulatory blood pressure monitoring
  • determination of various serum markers and cardiac ultrasound.
  • evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
02

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Blood Pressure Measurement
  • Atrial Fibrillation
  • Blood pressure measurement in atrial fibrillation
  • Atrial Fibrillation diagnosis
03

In context

Atrial Fibrillation

3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.

This study's planned enrollment of 100 is below the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

University of Athens is the lead sponsor of 133 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

SUBJECTS REFERRED TO HYPERTENSION CENTER

Inclusion criteria

  • Hypertensives adults in atrial fibrillation

Exclusion criteria

Exclusion Criteria:

  • Renal disease (Cr > 2 mg/l).
  • Patients with pacemaker rhythm during the study.
  • Each patient with acute disease (inflammation, surgery), malignancy, collagen diseases, pulmonary fibrosis, renal failure, liver failure, chronic inflammatory diseases.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)

Groups and cohorts

  • AF

    Hypertensive patients in AF

  • Non-AF

    Hypertensive Patients

06

What researchers measure

Primary outcomes

  1. Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in atrial fibrillation (AF)

    1. Evaluation of the oscillometric technique of an electronic device in blood pressure measurement. 2. Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes. 3. Evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Hypertension Center, Third Internal Medicine Dpt, University of Athens
    Athens, Greece
    • George S. Stergiou · Contact · gstergi@med.uoa.gr · 00302107763117
    • George S. Stergiou, Professor · Contact · gstergi@med.uoa.gr · 00302017763117
    • Antonios Th. Destounis, Phd candidate · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01088269
Lead sponsor
University of Athens
Responsible party
George S. Stergiou (Associate Professor of Medicine and Hypertension, University of Athens) — Principal investigator
First posted
Mar 17, 2010
Start date
Mar 2010
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Sep 14, 2017

Study contacts

George S Stergiou, MD
Contact
gstergi@med.uoa.gr
+302107763117
George S Stergiou, MD
study chair · Hypertension Center,Third Department of Medicine,University of Athens,Greece

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Atrial Fibrillation→

Other studies from this sponsor

University of Athens

Start the discussion